Background & Opportunity
Background and opportunity: PharmaSGP is an asset-light consumer health platform that uses owned and acquired OTC brands to cover multiple therapeutic areas. It combines pharmacy sales, D2C activity, and multichannel media investment to promote products in Germany and other European markets. The company already had established brands, regulatory capabilities, pharmacy access, and a marketing system, so growth did not have to depend entirely on new production assets or a single brand. During 2020–2021, growth in the existing business slowed, making broader therapeutic coverage and portfolio expansion a new management priority. In 2021, revenue was €65.3m, up 3.3%; adjusted EBITDA was €19.4m, with an adjusted EBITDA margin of 29.7%. These figures showed that the company still had profitability and a functioning platform, but that continued natural expansion based only on its existing Health Brands had limits. The opportunity was not simply to add another product. It was to find mature OTC brands with existing market recognition, access to relevant channels, and the potential for rapid integration into PharmaSGP’s regulatory and marketing infrastructure. On June 15, 2021, PharmaSGP announced the acquisition of GSK’s Baldriparan, Formigran, Spalt, and Kamol brands. Company materials state that the brands entered PharmaSGP’s portfolio in September 2021. The transaction expanded therapeutic coverage and brand reach, allowing the platform to move from growth centered on a single health-brand base toward expansion through a multi-brand portfolio. The logic of acquiring mature brands was that the brands could supplement the product range while PharmaSGP applied its asset-light model, regulatory capabilities, pharmacy channels, and D2C multichannel marketing. The company discloses reach of more than 1.7亿 relevant target-group contacts per month and describes acquisitions and integration as ways to expand therapeutic areas and European markets. Media spending alone was not the answer. The important combination was brand equity, channel access, regulatory capability, and marketing execution, enabling new brands to plug into the existing platform. The acquisition also created a path for continued European expansion and future M&A. Mature brands could be managed and promoted on an existing commercial foundation rather than built from zero. However, the evidence has clear limits. Public disclosures do not separately report revenue, profit, or market share for the four acquired brands, nor do they split 2022 growth between acquisition contribution and organic growth. The acquisition should therefore be understood as the core decision that changed the portfolio and growth path, not as proof that the entire financial increase came from the transaction. The annual report explicitly states that 2022 revenue growth came from both the existing product portfolio and the products acquired in 2021. The real opportunity was to strengthen the platform with mature brands, not to replace the existing business with one transaction.
Original Problem / Model
Original problem and model: Existing-business growth had slowed. Revenue was €65.3m in 2021, with the company relying mainly on its existing Health Brands. PharmaSGP needed broader therapeutic coverage and a larger brand portfolio while preserving its asset-light and scalable operating model.
Turning Point
Key turning point: On June 15, 2021, PharmaSGP announced the acquisition of four GSK OTC brands. The transaction entered the company’s portfolio in September 2021 and became a representative move in its M&A-led growth strategy.
Core Decision
Core decision: Acquire mature brands instead of relying solely on organic growth, then connect those brands to PharmaSGP’s existing regulatory capabilities, pharmacy channels, and D2C multichannel marketing system.
Execution / Model / Acquisition Changes
Execution, business model, and customer acquisition change: PharmaSGP added Baldriparan, Formigran, Spalt, and Kamol to its portfolio. It used the asset-light platform, multichannel media investment, pharmacy sales, and D2C reach to promote products across multiple therapeutic areas while continuing European market expansion.
Measurable Results
Quantified result: 2022 revenue was €85.824m, up 31.3% from 2021; adjusted EBITDA was €28.229m, up 45.3%, and the margin rose from 29.7% to 32.9%. Revenue subsequently increased from €101.1m in 2023 to €118.8m in 2024. Public disclosures do not separate the contribution of the acquired brands.
Lessons
Lesson and implication: Mature brands create portfolio value only when they are connected to an existing platform. Evaluation should consider acquisition integration, channel access, and marketing capability together, while clearly separating acquisition contribution from organic growth.